Acellular Dermal Matrices Market Analysis & Forecast: 2025-2032

Acellular Dermal Matrices Market is estimated to be valued at USD 11.05 Bn in 2025 and is expected to reach USD 24.58 Bn in 2032, exhibiting a compound annual growth rate (CAGR) of 12.1% from 2025 to 2032.

Analysts’ Views on Global Acellular Dermal Matrices Market:

Rising developments and technological advancements in acellular dermal matrices can drive the global acellular dermal matrices market growth over the forecast period. Furthermore, continuous research & development (R&D) activities can improve the performance and cost-effectiveness of acellular dermal matrices, and can offer new market future opportunities.

Figure 1. Global Acellular Dermal Matrices Market Share (%), By Origin, 2025

To learn more about this report, Request sample copy

Global Acellular Dermal Matrices Market – Drivers

• Increasing demand for cosmetic and reconstructive surgeries: Acellular dermal matrices are frequently utilized in plastic and reconstructive surgery including  breast reconstruction and facial aesthetics. Growing demand for cosmetic and reconstructive procedures is expected to drive the market growth.
• For instance, in 2022, according to the American Society of Plastic Surgeons (ASPS), a non-profit organization, total cosmetic surgery treatments in the U.S. were 576,485 in 2022, indicating increase of 19% from 2019. This total number of breast category operations were 575,492, which increased by 15% from 2019. These surgeries include breast augmentation, breast lift (mastopexy), and breast reductions.
• Product launches or approvals: Market players are focusing on product launches of new acellular dermal matrices (ADM), and this is expected to drive the global acellular dermal matrices market growth over the forecast period. For instance, in April 2023, MTF Biologics, a global non-profit organization, launched AlloPatch Pliable Meshed to its portfolio of superior, creative, and effective wound care treatments. AlloPatch Pliable Meshed is an acellular human reticular dermal allograft meant to aid in the healing of difficult-to-heal lesions such as diabetic foot ulcers and venous leg ulcers.

Figure 2. Global Acellular Dermal Matrices Market Share (%), By Region, 2025

To learn more about this report, Request sample copy

Global Acellular Dermal Matrices Market - Regional Analysis

Among region, North America is estimated to hold a dominant position in the global acellular dermal matrices market over the forecast period. North America is estimated to hold 43.2 % of the market share in 2025. The market is expected to witness significant growth in the near future due to increasing product launches in the region. For instance, in April 2022, LifeNet Health, a U.S.-based biotechnology company, announced the launch of its unique allograft treatments for wounds at the 2022 Symposium on Advanced Wound Care (SAWC) Spring Conference, held from April 7-9, 2022, in Phoenix, Arizona, U.S. Its flagship biologic portfolio includes Matrion, the first full-thickness decellularized placental membrane for wounds, and Dermacell AWM, the first acellular dermal matrix clinically shown to effectively cure wounds in as little as one treatment.

Global Acellular Dermal Matrices Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization (WHO) declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others faced problems regarding transportation of things from one place to another.

The COVID-19 pandemic had negative impact on the global acellular dermal matrices market, owing to delayed surgeries and procedures. During the peak of the pandemic, many elective surgeries and non-urgent medical procedures were postponed or to conserve healthcare resources and limit the risk of transmission. This most likely resulted in decrease in demand for acellular dermal matrices for these treatments.

Global Acellular Dermal Matrices Market - Segmentation

Global acellular dermal matrices market is segmented into origin, application, place of setting, and region.

• By origin, the market is segmented into human dermis, porcine dermis, and bovine dermis. Porcine dermis segment is expected to hold a dominant position in the global acellular dermal matrices market over the forecast period due to increasing launch of porcine dermis based acellular dermal matrices.
• By application, the market is segmented into acute wounds (burns, trauma, cancers, and infections), chronic wounds (diabetic foot ulcers, venous leg ulcers, pressure ulcer, and others) and reconstruction procedures (abdominal wall procedures, breast procedures, orthopedic procedures, and others). Out of which, reconstruction procedures segment is expected to dominate the market over the forecast period due to increasing number of reconstruction surgeries.
• By place of setting, the market is segmented into hospitals (in- patient, out- patient), ambulatory surgical centers, and office based. Out of which, hospitals segment is expected to dominate the market over the forecast period due to rising launch of cosmetic hospitals in U.S.
• By region, the market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. Out of which, North America is expected to dominate the market over forecast period due to increasing approval of products by the regulatory authorities in the region.

Among all the segmentation, the application segment is expected to dominate the market over the forecast period due to increasing use of ADM in reconstruction surgeries.

Global Acellular Dermal Matrices Market - Cross Sectional Analysis

Among place of setting, hospitals segment is expected to be dominant in the Middle East region, owing to increasing launch of cosmetic surgery hospitals. For instance, in July 2020, NMC Healthcare, one of the largest private healthcare company in the U.A.E., opened its new CosmeSurge Hospital in Jumeirah, U.A.E. The center, completed in December 2019, specializes in cosmetic surgery, and is situated near to the renowned Burj Al Arab. This will be the 17th facility under the CosmeSurge brand.

Global Acellular Dermal Matrices Market: Key Developments

• In April 2021, Integra LifeSciences Holdings Corporation, a global medical technology company and manufacturer of SurgiMend Collagen Matrix, issued a statement in response to the U.S. Food and Drug Administration (U.S.FDA) safety communication on the differences in the complication rates between acellular dermal matrix (ADM) products used in implant-based breast reconstruction. SurgiMend Collagen Matrix is approved by the U.S. FDA for use in specific types of operations to fortify tissue where weakness occurs such as cosmetic and reconstructive surgery and hernia repair.
• In December 2021, Aziyo Biologics, Inc., a commercial-stage regenerative medicine company, announced the completion of previously announced private investment in public equity (PIPE) funding. The PIPE financing was initiated by a fund linked with Birchview Capital, an investment management company with participation from existing investors such as funds affiliated with Deerfield Management Company, an investment firm and HighCape Capital, a growth equity fund.
• In July 2020, Organogenesis Holdings Inc., a regenerative medicine company that provides  a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, announced that the most recent advanced wound care research on its Apligraf, Affinity, Dermagraft, Nushield, and PuraPly AM product lines were showcased at the 2020 Symposium on Advanced Wound Care (SAWC) Spring | Wound Healing Society Virtual Experience held on July 24-26, 2020 in Florida, U.S.

Global Acellular Dermal Matrices Market: Key Trends

Collaborations and Partnerships: Market players are engaged in partnerships or collaborations, and this is expected to drive the global acellular dermal matrices market in the near future. In 2019, BioHorizons, a dental implant manufacturer, in partnership with Camlog, a supplier of premium dental implants, announced the CE certification of NovoMatrix, a novel acellular dermal matrix derived from porcine tissue and intended for soft tissue applications.

Global Acellular Dermal Matrices Market: Restraint

Regulatory challenges: Stringent regulatory approval processes for medical devices including acellular dermal matrices is expected to hinder the global acellular dermal matrices market growth. For instance, in March 2021, The U.S. Food and Drug Administration (FDA) released a safety communication external site pertaining to Acellular Dermal Matrices (ADM) products used in implant-based breast reconstruction. According to the U.S. FDA's review, two ADMs named FlexHD developed by MTF Biologics, a global non-profit organization and Allomax developed by BD, a medical device company may have a greater risk profile than others. Two years after surgery, there were greater incidence of serious problems, explanation, further procedures, and infections.

To counterbalance the restraint, key players should focus on increasing the safety and efficacy of ADM products.

Global Acellular Dermal Matrices Market - Key Players

Major players operating in the global acellular dermal matrices market include Integra LifeSciences Corporation, AbbVie Inc., Johnson & Johnson, HansBioMed, Becton, Dickinson and Company, Cook Group, Smith & Nephew Plc., Reprise Biomedical, Organogenesis Holdings Inc., Tissue Regenix, LifeNet Health, Zimmer Biomet Holdings, Inc., Stryker Corporation, MiMedx Group, PolyNovo Limited, Fidia Pharma USA Inc., Baxter International Inc., In2Bones Global, BioHorizons, Inc., Harbor MedTech, Inc., MLM Biologics Inc., Geistlich Pharma AG, Olaregen Therapeutix, Inc., EnColl Corporation, Kerecis limited, DSM, ACell Inc., 3M, Cell Constructs I, LLC, CG bio Inc., and Marine Polymer Technologies, Inc.

Definition: Acellular dermal matrices (ADMs) are surgical and medical devices that are used principally in the domains of plastic and reconstructive surgery, wound care, and tissue regeneration. These matrices are generated from human or animal sources, and go through a procedure that removes cellular components while keeping the extracellular matrix's (ECM) structure and functional features. Acellular dermal matrices have become indispensable tools in modern medicine by assisting in tissue restoration and reconstruction, particularly when natural tissue repair and regeneration are insufficient. The type of ADM utilized and how it is used are defined by a patient's individual medical condition and need, and are often done in collaboration with surgeons, healthcare practitioners, and tissue engineering specialists.